National Association of Testing Authorities, Australia
Scope of Accreditation
Mater Laboratory Services
Site
Mater Pathology
Accreditation No.
2623
Site No.
2616
Date of Accreditation
03 Aug 1987
Address
Mater Pathology Administration, Level 7 Mater Hospital Brisbane, Raymond Terrace
South Brisbane, QLD 4101
Australia
Contact
Ms Deb Hornsby P: +61 (07) 31635963
Availability
Services available to external clients
Supervision
GX (General)
Scope of Accreditation
Adult Intensive Care
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Anatomical Pathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of body fluids, exudates, washings and brushings from non-squamous mucosal sites for the detection of malignancy | Cerebrospinal fluid (CSF); Other body fluids; Sputum; Urine; Washings or brushings from other sites | Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations on samples obtained via fine needle aspiration biopsy | Fine needle aspirates (FNA) | Review and reporting of fine needle aspiration samples |
| Anatomical pathology - Tissue pathology - Examination of biopsy material | Formalin-fixed tissue | Review and reporting of biopsy material to identify or exclude morphological abnormalities |
| Anatomical pathology - Tissue pathology - Gene probes using paraffin in situ hybridisation techniques (chromogenic/silver) | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of nucleic acid targets - Various |
| Anatomical pathology - Tissue pathology - Immediate frozen section diagnosis | Fresh tissue | Intra-operative consultation and examination of biopsy material |
| Anatomical pathology - Tissue pathology - Immunohistochemical investigation | Fixed cytological smears; Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of antigenic targets - Various |
| Detection of antigenic targets - Various |
Cellular and Molecular Diagnostics
ISO 15189 (2022)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Investigation of haemolysis | Blood | Paroxysmal nocturnal haemoglobinuria (PNH) screen |
| Immunopathology - Characterisation of leucocyte surface antigens (including immunophenotyping) | Aspirates; Blood; Bone marrow; Cerebrospinal fluid (CSF); Fluids; Fresh tissue | Assessment of lymphoid cell populations; Assessment of myeloid cell populations |
| Immunopathology - Procedures related to the collection, processing, storage and issue of human haemopoietic progenitor cells | Blood; Haemopoietic progenitor cells | Enumeration of CD34+ cells |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Cerebrospinal fluid (CSF) | Escherichia coli; Neisseria meningitidis; Streptococcus agalactiae (Streptococcus group B); Streptococcus pneumoniae |
| Listeria monocytogenes | ||
| Faeces | Campylobacter spp.; Clostridioides difficile; Salmonella spp.; Shigella spp.; Yersinia spp. | |
| Fluids; Genital swabs; Urine | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Respiratory specimens | Bordetella pertussis; Mycoplasma pneumoniae | |
| Chlamydophila pneumoniae; Chlamydophila psittaci; Legionella longbeachae; Legionella pneumophila | ||
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (fungi) | Cerebrospinal fluid (CSF); Respiratory swabs | Cryptococcus gattii; Cryptococcus neoformans; Pneumocystis jirovecii |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Faeces | Cryptosporidium spp.; Entamoeba histolytica; Giardia lamblia |
| Genital swabs; Urine | Trichomonas vaginalis | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Amniotic fluid; Blood; Cerebrospinal fluid (CSF); Dry swabs; Respiratory specimens; Urine | Cytomegalovirus (CMV); Enterovirus |
| Blood | Hepatitis C virus (HCV) viral RNA | |
| Hepatitis B virus (HBV) DNA; Hepatitis C virus (HCV) viral RNA | ||
| Cerebrospinal fluid (CSF) | Herpes simplex virus (HSV); Varicella zoster virus (VZV) | |
| Dry swabs; Respiratory specimens; Urine | Herpes simplex virus (HSV); Varicella zoster virus (VZV) | |
| Eye swabs; Urine | Adenovirus | |
| Faeces | Adenovirus; Astrovirus; Norovirus; Rotavirus A; Sapovirus | |
| Nasal aspirates/washes; Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasal aspirates/washes; Nasal swabs; Nasopharyngeal swabs | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasopharyngeal and throat swab; Nasopharyngeal swabs; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Respiratory specimens | Adenovirus; Human metapneumovirus; Influenza A virus; Influenza B virus; Parainfluenza virus type 1/2/3/4; Picornavirus; Respiratory syncytial virus (RSV) A/B | |
| Microbiology - Mycobacteriology - Tests for cell mediated immunity | Plasma | Interferon-γ (IFN-γ) release assays |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Plasma; Serum | Hepatitis A virus antibody (anti-HAV) - IgG; Hepatitis A virus antibody (anti-HAV) - IgM; Hepatitis B virus core antibody (anti-HBc) - Total; Hepatitis B virus surface antibody (anti-HBs); Hepatitis B virus surface antigen (HBs Ag); Hepatitis C virus (HCV); Human immunodeficiency virus (HIV) |
| Syphilis Treponema pallidum antibody | ||
| Syphilis Treponema pallidum antibody | ||
| Serum | Bordetella pertussis total antibody; Cytomegalovirus (CMV); Epstein-Barr virus; Helicobacter pylori; Hepatitis B virus core antibody (anti-HBc) - IgM; Hepatitis B virus envelope antibody (anti-HBe); Hepatitis B virus envelope antigen (HBe Ag); Hepatitis C virus (HCV); Herpes simplex virus (HSV); Human T-lymphotropic virus type I/II (HTLV-I/II) antibody; Measles virus; Mumps virus; Parvovirus; Rubella IgG antibody; Rubella IgM antibody; Syphilis Treponema pallidum antibody; Toxoplasma gondii; Varicella zoster virus (VZV) | |
| Mycoplasma pneumoniae |
Diabetic Centre
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
Division of Chemical Pathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of calculus | Calculi | Ammonium; Calcium; Carbonate; Cysteine; Magnesium; Oxalate; Phosphate; Urate |
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Plasma; Serum | Ethanol; Paracetamol (acetaminophen); Salicylate |
| Chemical pathology - Biochemical genetic services - Amino acid quantitation | Urine | Pyruvate or other amino acids |
| Chemical pathology - Biochemical genetic services for the diagnosis of metabolic and enzymological disorders | Cerebrospinal fluid (CSF); Plasma; Serum | Amino acids |
| Urine | Organic acids | |
| Mucopolysaccharides (MPS) | ||
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Plasma; Serum | Carbamazepine; Gentamicin (cidomycin, septopal, genticyn, garamycin); Lithium; Phenytoin (dilantin); Tobramycin; Valproate (valproic acid, epilim); Vancomycin |
| Digoxin; Methotrexate | ||
| Chemical pathology - Detection and/or quantitation of tumour markers | Serum | Human chorionic gonadotropin (hCG) |
| CA125 antigen (CA125); CA15-3 antigen (CA15-3); CA19-9 antigen (CA19-9); Carcinoembryonic antigen (CEA); Human epididymal protein 4; Prostate specific antigen (PSA) - Free; Prostate specific antigen (PSA) fractions and derived index; α-Fetoprotein (AFP); β2-Microglobulin (B2M) | ||
| Chemical pathology - Detection of faecal occult blood | Faeces | Blood |
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Blood | 17α-Hydroxyprogesterone |
| Serum | Adrenocorticotropic hormone (ACTH); C-peptide; Growth hormone; Insulin-like growth factor-binding protein 3 (IGF-BP3); Sex hormone binding globulin (SHBG) | |
| Cortisol; Follicle stimulating hormone (FSH); Insulin; Insulin-like growth factor 1 (IGF-1, somatomedin C); Luteinising hormone (LH); Macroprolactin; Oestradiol; Progesterone; Prolactin | ||
| 17α-Hydroxyprogesterone; Androstenedione; Dehydroepiandrosterone sulfate (DHEAS); Oestradiol; Testosterone | ||
| Parathyroid hormone (PTH) | ||
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
| Chemical pathology - Dynamic tests | Sweat | Sweat chloride |
| Chemical pathology - Further investigation of cardiac function | Plasma | Troponin I |
| Plasma; Serum | N-Terminal-pro b-type natriuretic peptide (NT-proBNP) | |
| Chemical pathology - Further investigation of lipid profiles for diagnosis of types III and IV hyperlipidaemia | Plasma; Serum | HDL - Quantitation |
| Chemical pathology - Further investigation of renal and/or hepatic function | Other body fluids; Serum | Bile acids - Quantitative |
| Serum | Alkaline phosphatase (ALP) isoenzymes | |
| α1-Antitrypsin | ||
| Haptoglobins | ||
| Chemical pathology - Haem related pigments and precursors (excluding porphyria) | Cerebrospinal fluid (CSF) | Bilirubin; Xanthochromia |
| Urine | Myoglobin | |
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Ascitic fluid; Drainage fluid; Faeces; Pleural fluid | Albumin; Glucose; Lactate dehydrogenase (LDH); Protein - Total |
| Cerebrospinal fluid (CSF) | Glucose; Protein - Total | |
| Plasma; Serum | C-reactive protein (CRP); High sensitivity C-reactive protein (CRP) | |
| Alanine aminotransferase; Albumin; Alkaline phosphatase; Ammonia; Amylase; Aspartate aminotransferase; Bicarbonate; Bilirubin - Any fractions; Calcium - Corrected for albumin; Chloride; Cholesterol - Total; Cholinesterase; Creatine kinase; Glucose; Lactate; Lactate dehydrogenase (LDH); Lipase; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea; γ-Glutamyltransferase | ||
| Creatinine | ||
| Plasma; Serum; Urine | Osmolality | |
| Serum | Angiotensin converting enzyme (ACE) | |
| Urine | pH | |
| Albumin; Creatinine; Microalbumin | ||
| Amylase; Calcium - Total; Chloride; Creatinine; Glucose; Magnesium; Phosphate; Potassium; Sodium; Urate; Urea | ||
| Bilirubin - Total; Blood; Glucose; Ketones; Leucocyte esterase; Nitrite; Protein - Total; Specific gravity; pH | ||
| Chemical pathology - Investigation for folate deficiency | Blood; Serum | Folate; Red blood cell folate |
| Chemical pathology - Investigation of Helicobacter pylori colonisation or eradication | Breath | Urease |
| Chemical pathology - Investigation of maternal markers for pre-eclampsia | Plasma; Serum | FMS-like tyrosine kinase 1 - Soluble |
| Chemical pathology - Investigation of maternal markers to detect foetal abnormality | Plasma; Serum | Free β-human chorionic gonadotropin (free β-hCG); Placental growth factor (PGF, PLGF); Pregnancy associated plasma protein A (PAPP-A) |
| Chemical pathology - Investigation of porphyria | Urine | Porphobilinogen (PBG); Porphyrins - Total |
| Chemical pathology - Iron studies | Plasma; Serum | Ferritin; Iron; Transferrin |
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
| Chemical pathology - Quantitation of precursor and intermediary metabolites | Blood | Pyruvate |
| Plasma; Serum | Homocysteine | |
| Essential fatty acids | ||
| Serum | Free fatty acids - Total; β-Hydroxybutyrate | |
| Urine | Creatine; Guanidinoacetate | |
| Chemical pathology - Quantitation of vitamin B markers | Serum | Methylmalonic acid (MMA) |
| Holotranscobalamin (active vitamin B12) | ||
| Chemical pathology - Quantitation of vitamins | Serum | Retinol (vitamin A); Tocopherol (vitamin E) |
| 25-Hydroxyvitamin D; Cobalamin (vitamin B12) | ||
| Chemical pathology - Tests for thyroid function | Serum | Thyroid stimulating hormone (TSH); Thyroxine (T4) - Free; Triiodothyronine (T3) - Free |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Rheumatoid factor |
| Anti-thyroglobulin antibodies (Tg); Anti-thyroid peroxidase antibodies (TPO) | ||
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Faeces | Calprotectin |
| Plasma; Serum; Urine | Cryoglobulins; Detection and amount of paraproteins; Protein classes | |
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Serum | Immunoglobulin subclasses; Total immunoglobulin A; Total immunoglobulin G; Total immunoglobulin M |
| Infertility and pregnancy tests including assisted reproductive technology - Diagnosis of pregnancy | Urine | Human chorionic gonadotropin (hCG) |
| Infertility and pregnancy tests including assisted reproductive technology - Diagnosis or follow up of threatened abortion and/or diagnosis of ectopic pregnancy | Serum | Human chorionic gonadotropin (hCG) - Quantitative total |
Division of Microbiology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Microbiology - Bacteriology - Detection and identification of crystalline material | Synovial fluid | Crystal detection and identification |
| Microbiology - Bacteriology - Detection of pathogenic bacteria | Aspirates; Cerebrospinal fluid (CSF); Ear swabs; Eye swabs; Fluids; Genital swabs; Operative specimens; Respiratory specimens; Synovial fluid; Tissues; Urine; Wound swabs | Bacteria; Pathogenic microorganisms |
| Aspirates; Fluids; Operative specimens; Synovial fluid; Tissues | Bacteria; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | |
| Bacterial isolates | Pathogenic identification and antibiotic susceptibility | |
| Pathogenic identification and antibiotic susceptibility | ||
| Blood | Bacteria; Pathogenic microorganisms | |
| Bacteria; Pathogenic microorganisms | ||
| Cerebrospinal fluid (CSF) | Bacteria; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | |
| Ear swabs; Eye swabs; Respiratory specimens | Bacteria; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | |
| Faeces | Campylobacter spp.; Clostridioides difficile; Salmonella spp.; Shigella spp.; Vibrio spp.; Yersinia spp.; Bacteria | |
| Helicobacter pylori | ||
| Clostridioides difficile toxin | ||
| Helicobacter pylori | ||
| Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | ||
| Genital swabs | Bacteria; Leucocytes (white blood cells, WBC) | |
| Urine | Legionella antigen | |
| Streptococcus pneumoniae antigen | ||
| Bilirubin; Blood; Glucose; Ketones; Leucocyte esterase; Nitrite; Proteins; Specific gravity; Urobilinogen; pH | ||
| Bacteria; Casts; Crystals; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC); Red blood cell morphology | ||
| Wound swabs | Bacteria; Epithelial cells; Leucocytes (white blood cells, WBC) | |
| Microbiology - Bacteriology - Detection of pathogenic bacteria for epidemiological infection control surveillance | Groin swabs; Nasal swabs; Perianal swabs; Umbilicus | Carbapenem resistant Acinetobacter (CRAB); Carbapenem resistant Enterobacteriaceae (CRE); Extended spectrum beta-lactamases (ESBL); Methicillin resistant Staphylococcus aureus (MRSA); Vancomycin resistant Enterococci (VRE) |
| Microbiology - Environmental investigations and/or infection control (Clinical non-human testing) | Air; Spore strips | Bacterial growth - Sterility |
| Blood transfusion bags | Bacterial growth - Sterility | |
| Blood transfusion bags; Environmental swabs; Gastrointestinal endoscopes; Vascular catheter tips | Bacterial growth - Sterility | |
| Dialysis waters | Bacterial growth - Sterility | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Nasal swabs; Nasopharyngeal swabs; Oropharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) |
| Nasopharyngeal aspirate; Respiratory specimens | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV) | |
| Microbiology - Mycobacteriology - Detection and identification of mycobacteria | Blood; Cerebrospinal fluid (CSF); Other body fluids; Respiratory specimens; Sputum; Tissues; Urine | Mycobacteria detection |
| Culture and limited identification | ||
| Microbiology - Mycology - Detection, isolation and/or identification of yeasts and/or fungal elements | Aspirates; Blood; Cerebrospinal fluid (CSF); Fluids; General swabs; Genital swabs; Hair; Nails; Ocular specimens; Respiratory swabs; Serum; Skin; Skin scrapings; Sputum; Tissues; Urine; Wound swabs | Fungi detection; Fungi isolation; Yeast detection; Yeast isolation |
| Isolates | Yeasts identification | |
| Fungi susceptibility; Yeast susceptibility | ||
| Fungi identification; Yeasts identification | ||
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Faeces | Strongyloides stercoralis |
| Faeces; Urine | Cysts; Ova; Parasites | |
| Microbiology - Virology - Detection of pathogenic viruses | Faeces | Norovirus |
| Adenovirus; Rotavirus |
Division of Molecular Genetics
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Cytogenetics - Detection of defined, balanced and/or unbalanced chromosomal abnormalities by in situ hybridisation techniques | Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Other tissues - Malignant; Other tissues - Non-malignant; Paraffin embedded tissue | Cytogenetic analysis and reporting |
| Cytogenetics - Karyotype detection of balanced and/or unbalanced chromosome abnormalities | Amniotic fluid; Blood; Chorionic villus tissue; Other tissues - Non-malignant | Constitutional genetic abnormalities |
| Cytogenetics - Molecular karyotype (SNP microarray) detection of unbalanced chromosome abnormalities | Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Other tissues - Malignant; Other tissues - Non-malignant | Cytogenetic analysis and reporting |
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Blood | Factor V Leiden; HLA-B locus typing; Haemochromatosis; Nucleic acid analysis for specific variants; Prothrombin variant |
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted panels for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA; Tissues | Nucleic acid analysis for specific variants |
| Molecular genetics - DNA extraction | Amniotic fluid; Blood; Buccal swabs; Chorionic villus tissue; Formalin-fixed paraffin-embedded (FFPE) tissues; Tissues; Urine | Viable DNA for sequencing |
| Molecular genetics - DNA fragment size analysis | Amniotic fluid; Blood; Chorionic villus tissue; Extracted DNA; Tissues | DNA fragment size determination; Maternal cell contamination |
| Molecular genetics - DNA sequencing | Amniotic fluid; Blood; Chorionic villus tissue; Extracted DNA; Tissues | Sequenced DNA by Sanger sequencing |
| Sequenced DNA utilising massively parallel sequencing technologies | ||
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes | Blood; Bone marrow; Formalin-fixed paraffin-embedded (FFPE) tissues; Tissues | BRAF mutation analysis; EGFR mutation analysis |
| Blood; Bone marrow; Tissues | Acute lymphoblastic leukaemia; Chronic myeloid leukaemia (CML); Myeloproliferative neoplasms; Quantitative calculation of p210 positive BCR::ABL1 transcripts; Solid tumours | |
| Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Targeted genes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA; Tissues | Adenylosuccinate lyase deficiency; Angelman syndrome; Congenital adrenal hypoplasia; Diabetes insipidus; Fragile X; Hyperuricemia; Ornithine transcarbamylase deficiency; Prader-Willi syndrome; Rett syndrome; Short stature; α-Thalassaemia |
| Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Targeted panels for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA; Tissues | Maturity onset diabetes of the young (MODY) |
| Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted genes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA; Tissues | Adenylosuccinate lyase deficiency; Angelman syndrome; Congenital adrenal hypoplasia; Diabetes insipidus; Fragile X; Hyperuricemia; Ornithine transcarbamylase deficiency; Prader-Willi syndrome; Rett syndrome; Short stature; α-Thalassaemia |
| Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted panels for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA; Tissues | Disorders of sexual development; Familial hypercholesterolemia; Familial hyperinsulinism; Hereditary breast and ovarian cancer syndrome; Hereditary polyposis syndrome; Lynch syndrome; Maturity onset diabetes of the young (MODY); Permanent neonatal diabetes; RASopathy syndromes |
| Molecular genetics - Predictive genetic testing - Targeted genes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA; Tissues | Congenital adrenal hyperplasia; Fragile X; α-Thalassaemia |
| Molecular genetics - Predictive genetic testing - Targeted panels for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA; Tissues | Familial hypercholesterolemia; Hereditary breast and ovarian cancer syndrome; Hereditary polyposis syndrome; Lynch syndrome; Maturity onset diabetes of the young (MODY) |
| Molecular genetics - Prenatal genetic testing (excluding non-invasive prenatal [genetic] screening) | Amniotic fluid; Chorionic villus; Cord blood | Adenylosuccinate lyase deficiency; Androgen receptor; Congenital adrenal hyperplasia; Hyperuricemia; Ornithine transcarbamylase deficiency; RASopathy syndromes |
| Molecular genetics - RNA extraction | Blood | Viable RNA for sequencing |
| Molecular genetics - Screening for an unknown mutation - Targeted genes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA; Tissues | Adenylosuccinate lyase deficiency; Angelman syndrome; Congenital adrenal hyperplasia; Diabetes insipidus; Fragile X; Ornithine transcarbamylase deficiency; Prader-Willi syndrome; Rett syndrome; Short stature; α-Thalassaemia |
| Molecular genetics - Screening for an unknown mutation - Targeted panels for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Chorionic villus | Disorders of sexual development; Familial hypercholesterolemia; Familial hyperinsulinism; Hereditary breast and ovarian cancer syndrome; Hereditary polyposis syndrome; Lynch syndrome; Maturity onset diabetes of the young (MODY); Permanent neonatal diabetes; RASopathy syndromes |
| Molecular genetics/Cytogenetics - Bioinformatic analysis | DNA sequences | Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation |
Emergency Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Haematology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Blood | Snake venom detection |
| Haematology - Assessment of haemolysis or metabolic enzymes (red cell enzyme assays) | Blood | Glucose-6-phosphate dehydrogenase (G6PD) |
| Haematology - Bone marrow examination | Bone marrow | Examination of aspirated material |
| Haematology - Diagnosis of thalassemia | Blood | Haemoglobin A2 (HbA2) - Quantitation; Haemoglobin F (HbF) - Quantitation |
| Haematology - Examination of blood films by special staining | Blood | Malaria |
| Haemosiderin | ||
| Heinz bodies | ||
| Microfilaria | ||
| Haematology - Foetal haemoglobin in maternal circulation | Blood | Detection and quantitation of foetal red cell antigens |
| Detection and quantitation of foetal red cell antigens | ||
| Haematology - Full blood examination | Blood | Morphology |
| Differential number; Erythrocyte count (red blood cell count, RBCC); Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Leucocyte count (white blood cell count, WBCC); Mean platelet volume (MPV); Nucleated red blood cells (NRBC); Platelet count; Red blood cell index or indices; Reticulocytes | ||
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | Platelet function (PFA) |
| Plasma | APTT heparin neutralisation; Activated partial thromboplastin time (APTT); Activated protein C (APC) resistance; Anti-Xa - Apixaban; Anti-Xa - Rivaroxaban; Anti-Xa activity - Heparin activity; Anti-thrombin III; D-dimer; Echis test; Factor II; Factor IX; Factor V; Factor VII; Factor VIII; Factor X; Factor XI; Factor XII; Factor XIII; Fibrinogen; International normalised ratio (INR); Lupus anticoagulant; Mixing studies - APTT; Prekallikrein (PK); Protein C and protein S; Prothrombin time (PT); Prothrombin time (PT) mixing studies; Thrombin time (TT) | |
| Heparin induced thrombocytopenia (HIT) - Confirmatory; Von Willebrand factor (vWF) activity - Ristocetin co-factor assay; Von Willebrand factor (vWF) antigen - Quantitation | ||
| Factor XIII | ||
| Haematology - Limited blood examination | Blood | Erythrocyte (RBC) sedimentation rate (ESR) |
| Immunohaematology - Blood grouping | Blood | ABO; RhD |
| Cord blood | ABO; RhD | |
| Immunohaematology - Determination of compatibility of blood donor units | Blood | Direct antiglobulin test (DAT, direct Coombs test); Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies |
| Immunohaematology - Identification and quantitation of blood group antibodies | Blood | Antibody elution |
| Cord blood | Direct antiglobulin test (DAT, direct Coombs test) | |
| Plasma | Other blood group antibodies; Red blood cell phenotyping; Rh | |
| Immunohaematology - Investigation of blood transfusion reactions | Blood products | Antibodies; Contamination - Microbiological; Direct antiglobulin test (DAT, direct Coombs test); Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies |
| Immunohaematology - Issue and release of blood and blood product for transfusion | Blood; Blood products; Cryoprecipitate; Fresh frozen plasma (FFP); Platelets | Issue and release of blood and blood products for transfusion |
| Immunohaematology - Storage and distribution of blood and blood components | Blood; Blood products; Cryoprecipitate; Fresh frozen plasma (FFP); Platelets | Compliance with transport, storage and distribution requirements of blood, products and components |
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Blood | Malaria |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood | Infectious mononucleosis |
Labour Ward
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Mater at Home
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Blood | Anion gap; Calcium - Ionised; Chloride; Creatinine; Glucose; Potassium; Sodium; Total carbon dioxide (TCO2); Urea |
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Lactate; Oxygen saturation (sO2); Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Total carbon dioxide (TCO2); pH |
| Haematology - Full blood examination | Blood | Haematocrit (packed cell volume, PCV); Total haemoglobin - Calculated |
MAYAC
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
Neonatal Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Private Intensive Care
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Queensland Diabetic Endocrine Clinic (High Risk Foot Clinic)
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
Recovery Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Stem Cell Transplant Laboratory
ISO 15189 (2022)
Human Pathology
Medicare expiry date
11 Mar 2026
Last Activity Date
06 Jun 2024
| Service | Product | Determinant |
|---|---|---|
| Immunopathology - Procedures related to the collection, processing, storage and issue of human haemopoietic progenitor cellsAutologous collection and/or processing: Products received from AN 17013 SN 18554 and AN 18812 SN 20950. | Haemopoietic progenitor cells | Processing; Storage (includes freezing/thawing) |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
2623
Site No.
2616
Print date
27 Nov 2024
END OF SCOPE